The International AIDS Vaccine Initiative (IAVI) said this week that Dr. Moncef Slaoui, chairman of Global Vaccines at GlaxoSmithKline (GSK), has joined its board of directors.
"Vaccines provide a light of hope across the spectrum of infectious diseases," Slaoui said. "I am honored to help IAVI continue and expand its important efforts to bring the world a vaccine to help end the enormous suffering and loss wrought by HIV/AIDS."
Slaoui received his doctorate in molecular biology and immunology at the Universite Libre de Bruxelles in Belgium. Slaoui attended Harvard Medical School and Tufts University School of Medicine for his postdoctoral studies. Early in his career, Slaoui worked at the University of Mons in Belgium as a professor of immunology. He has composed over 100 scientific presentations and papers.
Slaoui began his work at GSK in 1988. He gained responsibilities for research and development in 2006, vaccines in 2011 and new product franchises in 2012.
Slaoui has had instrumental roles in partnering GSK with the U.S. National Institutes of Health and other organizations as they collaborate to develop a vaccine for Ebola. The team has also developed new vaccines for cervical cancer and infantile gastroenteritis and has submitted a new malaria vaccine to regulatory approval.
He has been involved in other boards and committees, including the Advisory Committee to the Director of the National Institutes of Health, PhRMA, the Qatar Biomedical Research Institute Scientific Advisory Committee and Biotechnology Industry Organization. He has also advised the Qatar Foundation.
Slaoui has citizenship in Belgium, Morocco, and the U.S. and fluently speaks French, Arabic and English.
The IAVI Board of Directors provides a wide range of global expertise in the fields of academia, international development, health care, vaccinology, finance and clinical research.
"Moncef Slaoui brings a wealth of experience in translating promising research into practical vaccines for use throughout the world," IAVI President and CEO Margie McGlynn said. "His counsel will be crucial to ensuring the support needed to develop a vaccine against HIV/AIDS."